# AdvanSix Inc. (ASIX)

> Source: Nexqual · https://nexqual.com/ASIX · data as of 2026-10-23 16:40 UTC · cite as "Nexqual, AdvanSix Inc. (ASIX), nexqual.com/ASIX" · informational, not investment advice.

**Price:** USD 15.59 (-0.57% today) · US market open, as of October 23, 2026 at 16:40 UTC; quotes may be delayed. Prev close 15.68 · day 15.31–15.87 · 52w 14.1–26.73 · market cap $421M · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $1.56B, net income -$17.7M (-1.1% margin), free cash flow -$25.8M (SEC filings).
- Analysts: Hold (mean 2.50 on a 1–5 scale) (2 analysts), mean target USD 20 (range 18–22).
- Total return with dividends: 1Y -20.1% vs S&P 500 +14.6%; 5Y -64.0% vs S&P 500 +77.3%.
- Next earnings: 2026-11-04, EPS estimate USD -0.05, revenue estimate $426M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.68B | $1.95B | $1.53B | $1.52B | $1.52B | $1.56B |
| Gross profit | $274M | $314M | $165M | $153M | $165M | — |
| Net income | $140M | $172M | $54.6M | $44.1M | $49.3M | -$17.7M |
| EPS (diluted) | $4.81 | $5.92 | $1.95 | $1.62 | $1.80 | — |
| Free cash flow | $162M | $184M | $10.2M | $1.7M | $6.4M | -$25.8M |
| Gross margin | 16.3% | 16.2% | 10.8% | 10.1% | 10.8% | — |
| Net margin | 8.3% | 8.8% | 3.6% | 2.9% | 3.2% | -1.1% |
| Revenue growth | +45.5% | +15.5% | -21.2% | -1.0% | +0.3% | — |
| Cash + short-term investments | $15.1M | $31.0M | $29.8M | $19.6M | $19.8M | — |
| Total debt | $135M | $115M | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 0.3x · P/B 0.5x · FCF yield -6.12% · Earnings yield -4.21% · Dividend yield (paid, TTM) 4.09% · Buyback yield (TTM) 0.36%
P/E at fiscal year-ends: Dec 2025 9.6x, Dec 2024 17.6x, Dec 2023 15.4x.

## Analysts
Consensus Hold (mean 2.50 on a 1–5 scale), 2 analysts; mean target USD 20 (low 18, high 22).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-10 | Truist Securities | Target lowered | Hold | $20 → $18 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -20.1% | -64.0% |
| S&P 500 (SPY) | +14.6% | +77.3% |
| Per year | -20.1% | -18.5% |
| Volatility (annualized) | 53.4% | 44.5% |
| Max drawdown | -40.0% (May 2026→Oct 2026) | -70.6% (Mar 2022→Nov 2025) |

## Peers (Chemicals)
VHI (Valhi, Inc.) USD 13.96 -2.62% · RYAM (Rayonier Advanced Materials Inc) USD 6.94 +1.61% · BAK (Braskem SA) USD 1.66 +3.44% · TROX (Tronox Holdings plc) USD 3.45 -0.86% · LXU (LSB Industries, Inc.) USD 9.95 +1.90% · WLKP (Westlake Chemical Partners LP) USD 21 +0.19%

## More
Full page: https://nexqual.com/ASIX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in ASIX's own 10-K filed 2026-02-20 (https://www.sec.gov/Archives/edgar/data/1673985/000167398526000008/asix-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | Shaw Industries Group | "Our largest customer is Shaw Industries Group Inc. ("Shaw"), one of the world's largest consumers of caprolactam and Nylon 6 resin." |

Other companies that name ASIX in their own reports (relationship from ASIX's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | CVR PARTNERS, LP (UAN) | 10-K 2026-02-18 | "The performance graph below compares the cumulative total return of the Partnership's common units to (a) the cumulative total return of the S&P 500 Composite Index and (b) a composite peer group ("Pe…" |

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Plant Nutrients | $131.4M | 31.2% | -16.2% |
| Chemical Intermediates | $127.0M | 30.1% | +18.3% |
| Nylon | $100.2M | 23.8% | +26.1% |
| Caprolactam | $62.6M | 14.9% | -5.7% |
| Total revenue | $421.3M | 100% | — |

## Revenue by region (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| United States | $354.3M | 84.1% | -1.2% |
| International | $67.0M | 15.9% | +30.4% |
| Total revenue | $421.3M | 100% | — |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.04 | $0.25 | -118.0% | $426.0M | 2 |
| Next quarter (ends 2026-12-31) | $0.53 | $0.86 | -39.0% | $420.5M | 2 |
| Current fiscal year (ends 2026-12-31) | $0.18 | $2.51 | -92.6% | $1.67B | 2 |
| Next fiscal year (ends 2027-12-31) | $2.38 | $2.60 | -8.3% | $1.76B | 2 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-04): ±11.3%; last 8 reports averaged ±6.9%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 49.4% | ±11.3% |
| 2026-12-18 | 56 | 48.6% | ±15.4% |
| 2027-03-19 | 147 | 63.9% | ±31.6% |
| 2027-06-17 | 237 | 48.1% | ±29.8% |